Artemether

Quick links to important sections

Artemether

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Artemether

Quick Facts

Property Description
Active Ingredient Artemether (INN)
Primary Form Oral tablets; oily solution for intramuscular injection
Pharmacological Class Antimalarial, Blood Schizonticide
Origin Semi-synthetic derivative of artemisinin
Core Purpose Rapid reduction of parasites in acute infection

Artemether: A Semi-Synthetic Antimalarial Blood Schizonticide

Artemether is the International Nonproprietary Name (INN) for a potent anti-protozoal agent clinically recognized for its essential role in treating malaria. Pharmacologically, it is classified as an antimalarial and, more specifically, a blood schizonticide, as it targets the parasitic organisms during their multiplication phase in the bloodstream. Its primary feature is its fast speed of action compared to many conventional antimalarials.

Artemether is a semi-synthetic derivative of artemisinin, a compound sourced from the sweet wormwood plant (Artemisia annua). Its status is defined by its inclusion on the World Health Organization (WHO) Model List of Essential Medicines, indicating its established role and necessity in healthcare systems globally.

Chemical Origin, Formulation, and Combination Use

Chemically, Artemether is the methyl ether of dihydroartemisinin. The compound's lipid solubility is a key feature, influencing its formulation across pharmaceutical preparations, which include oral tablets and an oily solution for intramuscular injection where necessary.

The defining aspect of Artemether's use is its integration into Artemisinin-based Combination Therapies (ACTs), where it is paired with a longer-acting partner drug. This strategy is internationally recommended because it rapidly clears the parasites while enhancing overall efficacy, which is vital for preventing the development of drug resistance.

Regulatory References

  1. WHO Essential Medicines List
  2. NIH MedlinePlus on Artemether and Lumefantrine

What side effects are possible with Artemether?

Possible side effects and safety information

The safety profile for Artemether, primarily established through its use in combination therapy, is formally structured by regulatory bodies to categorize and communicate known adverse reactions. The official labeling classifies these effects by frequency and the specific system-organ class they affect.

Frequency-Classified Adverse Reactions

Adverse reactions that are officially listed as Common (may affect up to 1 in 10 people) typically include headache, dizziness, diarrhea, nausea, vomiting, pyrexia (fever), fatigue, insomnia, pruritus, and muscle or joint aches. Reactions classified as Uncommon (may affect up to 1 in 100 people) include somnolence (drowsiness), tremor, and paresthesia (tingling).

Many documented adverse effects are often noted as transient and may be difficult to distinguish from the symptoms of the acute malaria infection itself.

Serious Safety Considerations

The most clinically significant safety considerations documented in official regulatory sources relate to severe hypersensitivity reactions, such as anaphylaxis and angioedema, which represent a rare but documented risk. Furthermore, the official label notes the potential for prolongation of the QTc interval, an electrical change in the heart, classified as an uncommon finding.

This medication is formally contraindicated in individuals with a history of severe hypersensitivity to artemether or its components. Safety considerations for special populations include the need for caution and monitoring in patients with severe hepatic or renal impairment due to limited available clinical data.

Overdose and Emergency Response

The official regulatory profile for artemether is guided by the information available in the prescribing documents, which state that there is no specific clinical information documented regarding the symptoms or signs that result from an overdose exceeding the recommended therapeutic dose.

Overdose Scope

Scope Point Official Regulatory Statement
Documented Presentations No specific clinical manifestations are documented for high-dose exposure.
Antidote Information No specific antidote is listed as available for the management of overdosage.
Primary Management Treatment consists strictly of symptomatic and supportive therapy.

When to Seek Immediate Medical Help

Urgent medical attention is required in all suspected overdosage scenarios. Immediate emergency services must be called if the patient is experiencing any life-threatening clinical triggers, including collapse, a seizure, trouble breathing, or the inability to be awakened. In all cases of suspected overdosage, the Poison Control Center or emergency services must be contacted immediately for professional guidance.

As part of the official management protocol, required monitoring procedures include ECG monitoring (electrocardiogram) and blood electrolyte monitoring, initiated as deemed appropriate for the patient's clinical status. The overall regulatory structure emphasizes immediate professional intervention and defined supportive measures to address potential severe systemic effects.

Therapeutic Uses of Artemether

Artemether, used in combination therapy, is considered relevant in the management of acute malaria.

What Artemether Treats: Main Uses and Benefits

Artemether is applied in the management of acute, uncomplicated malaria, particularly against the multi-drug resistant Plasmodium falciparum parasite, a condition characterized by periods of heightened symptoms. The medication is commonly used in regions where resistance to older antimalarial drugs is an issue. It supports the primary therapeutic goal of parasite elimination, which contributes to the overall therapeutic process.

The medication is used to assist with symptom clusters that may become intense or disruptive, supporting the easing of acute manifestations like high fever, severe chills, headache, and muscle aches. This application helps patients cope more steadily with the difficult febrile episodes.

Its therapeutic applicability extends to vulnerable patient groups, including children and pregnant individuals across all trimesters for uncomplicated P. falciparum malaria, where supportive management is appropriate. The parenteral formulation may also be applied to assist with parasite management in conditions involving heightened systemic burden or when taking oral medication is difficult.


Quick Fact: Relief for Systemic Febrile Distress

Eligibility and Restrictions for Use

Artemether is approved for use in specific populations for the treatment of acute, uncomplicated malaria, while its use is strictly excluded or limited in others, according to regulatory labeling.

Who Must Not Use Artemether (Contraindications)

Artemether is formally contraindicated for patients with a known hypersensitivity to the drug or any other component in the formulation. Its use is also prohibited in individuals with a personal or family history of congenital QTc prolongation, symptomatic cardiac arrhythmias, clinically relevant bradycardia, or any other severe cardiac disease that may prolong the QTc interval. Additionally, patients with known electrolyte imbalances, such as uncorrected hypokalemia or hypomagnesemia, must not use the medicine.

Age and Physiological Restrictions

  • Pediatrics and Bodyweight: The medicine is indicated for adults and children with a bodyweight of 5 kg and above. Safety and efficacy are not established in infants weighing less than 5 kg.
  • Pregnancy: Use during the first trimester of pregnancy is generally restricted and should be avoided unless no suitable alternatives are available. It is often permitted during the second and third trimesters.
  • Organ Function: Patients with severe hepatic impairment or severe renal impairment should use the medicine with caution, as official data on safety in these specific groups are limited.
  • Severity of Infection: The oral formulation of Artemether is not approved for the treatment of severe or complicated malaria, restricting its use to uncomplicated cases only.

What should I know about interactions with other medicines?

Artemether Interactions with other medicines and products

Interactions with artemether are primarily driven by two clinical concerns: effects on the electrical activity of the heart (QT interval prolongation) and changes in drug concentration due to liver enzyme system activity.

Pharmacodynamic Interactions (QT Prolongation)

Coadministration with other medicines known to prolong the QT interval should generally be avoided. This includes specific antiarrhythmics (such as quinidine and quinine), certain antipsychotic and antidepressant agents, and various antibiotics. Concomitant use with these agents may result in an additive effect on the QT interval. Halofantrine should not be administered within one month of artemether use due to this potential additive risk.

Pharmacokinetic Interactions (CYP450 System)

Artemether, and its co-formulated partner lumefantrine, are metabolized by the liver enzyme CYP3A4. Coadministration with strong CYP3A4 inducers, such as rifampin, carbamazepine, phenytoin, and St. John's wort, is officially contraindicated. This combination can significantly decrease the concentrations of artemether/lumefantrine, leading to loss of therapeutic effectiveness.

Conversely, concurrent use with strong CYP3A4 inhibitors may increase drug levels, potentially increasing the risk of QT prolongation. Furthermore, the effectiveness of hormonal contraceptives may be reduced by the artemether regimen.

Mechanism of Action

Iron-Activated Cytotoxicity and Free Radical Generation

Artemether's primary action begins inside the parasite's food vacuole where it is activated by ferrous iron ( Fe^2+), a byproduct of hemoglobin digestion. This interaction cleaves the drug's peroxide bridge, generating highly reactive, cytotoxic free radicals. These radicals cause widespread oxidative damage and covalent modification to the parasite's essential proteins, nucleic acids, and membranes. This cascade results in widespread parasite cell death, which is the direct mechanistic cause of the drug's fast speed of action and the resulting rapid reduction of the parasite biomass.


Mechanistic Synergy and Stage Specificity

The cytotoxic mechanism specifically targets the asexual erythrocytic stages of the parasite. When used in combination therapy (ACT), Artemether provides the immediate, high-level reduction of the parasite population. This rapid, but short-lived, action is complemented by a long-acting partner drug that sustains inhibitory pressure to reduce the survival of residual organisms, thereby ensuring sustained clearance. The mechanism exhibits stage specificity, lacking activity against the dormant hypnozoite forms in the liver.

Dosage and Administration Information

How to Use Artemether: Administration Guidelines

This information describes the instructions for use of Artemether/Lumefantrine, focusing strictly on administration and dosing.

Administration Scope

Feature Instruction
Route Oral (PO) is the standard route. Intramuscular (IM) injection is an alternative for severe disease when other injectables are not available.
Timing with Meals Oral doses must be taken with food or a milky drink to ensure proper absorption.
Frequency A total of six doses administered over three days.
Procedural Steps If a patient vomits the oral dose within 1 to 2 hours of administration, a full repeat dose must be taken immediately. For patients unable to swallow, tablets may be crushed and mixed with a small amount of liquid or soft food and consumed at once.

Labeled Dosing Schedule (Artemether 20 mg/Lumefantrine 120 mg Tablets)

Dosing is determined strictly by the patient's body weight, and the full course of six doses must be completed.

Body Weight Dose per Administration (Total 6 Doses)
5 kg to <15 kg 1 tablet
15 kg to <25 kg 2 tablets
25 kg to <35 kg 3 tablets
geq 35 kg (Adults) 4 tablets

Treatment Schedule

The six doses are administered according to the following 60-hour schedule:

  1. Dose 1: Taken at the time of diagnosis (Hour 0).
  2. Dose 2: Taken 8 hours after the first dose.
  3. Dose 3 & 4: Taken twice daily (morning and evening) on Day 2.
  4. Dose 5 & 6: Taken twice daily (morning and evening) on Day 3.

The protocol defines a standardized, weight-dependent administration procedure for the fixed-dose combination. This procedure involves a three-day, six-dose timetable and requires co-administration with food to ensure proper absorption.

Recent Clinical Evidence

The clinical evidence for Artemether is rooted in Randomized Controlled Trials (RCTs) and systematic reviews, which form the primary scientific evidence base for official evaluations. Artemether is chiefly studied for its role as a component of Artemisinin-based Combination Therapies (ACTs).


Evidence for Acute, Uncomplicated Malaria

Research has explored the use of oral Artemether combinations for treating common Plasmodium falciparum malaria. Studies, predominantly short-term RCTs, have monitored two main results: the time until all parasites were undetectable (Parasite Clearance Time) and the resolution of symptoms along with the absence of parasites at follow-up checks (ACPR). Findings describe patterns observed in the studies that are associated with high measurements of parasite clearance and resolution at standard intervals (Day 28 or Day 42). The research has included broad populations of adults and children, though findings were mixed when compared across different geographic regions.


Evidence for Severe Malaria (Parenteral Use)

The evidence for the injectable formulation of Artemether comes from RCTs focused on hospitalized adults and children. The most critical outcome axis was studied for all-cause mortality. Other results monitored included the time to resolution of coma in patients with cerebral malaria. Studies reported that treatment was observed in some studies to be associated with measurements of mortality that were compared against older parenteral drugs like quinine. Patterns of time to consciousness were also explored alongside older treatments in specific large trials.


Summary of Evidence Gaps and Uncertainties

The evidence base contains specific gaps, particularly concerning long-term effects, which are not fully established beyond the typical Day 42 follow-up.

  • Comparative Evidence: Comparative evidence is lacking from direct trials challenging injectable Artemether against the currently preferred severe malaria treatment (artesunate) in all populations.
  • Special Groups: Data for certain groups remain insufficient, especially regarding use during the first trimester of pregnancy. Pharmacokinetic studies have also reported observations suggesting variable drug exposure in young children and women in the later stages of pregnancy, and the effect of this on measured outcomes remains uncertain.

Frequently Asked Questions (FAQ)

Common questions about Artemether (FAQ)

Q: Is Artemether the same thing as artemisinin?

A: Artemether is not the same as artemisinin, but it is closely related. According to official product information, Artemether is a semi-synthetic derivative of artemisinin, which is a natural compound sourced from the sweet wormwood plant (Artemisia annua).


Q: Are there any long-term side effects from taking Artemether?

A: Studies and official information indicate that long-term side effects beyond the standard treatment period are generally not fully established. This is because clinical trials typically monitor patients for a fixed, short-term period, usually up to 42 days, after starting treatment.


Q: Can taking Artemether make you tired or drowsy?

A: Regulatory documents list fatigue (tiredness) as a common side effect and drowsiness (somnolence) as an uncommon side effect. Due to the potential for these effects, caution is generally recommended.


Q: Is it safe to drive or operate machinery while on Artemether?

A: The official label notes that caution should be exercised regarding driving and operating machinery. This is due to the potential for side effects such as dizziness, somnolence (drowsiness), and unsteady walking (abnormal gait) which may impact the ability to perform these activities safely.


Q: Do infants require a special formulation of Artemether?

A: Official guidelines state that the medicine is indicated for children weighing 5 kg and above. For eligible children who may be unable to swallow the tablet whole, regulatory instructions state that tablets may be crushed and mixed with a small amount of liquid or soft food.


Q: Is it normal to feel dizzy while taking Artemether?

A: Yes, dizziness is listed in official documents as a common adverse reaction. This means it may affect up to 1 in 10 people who take the medication.


Q: How long does Artemether stay in your system?

A: Studies on the drug’s processing by the body show that Artemether and its active form are rapidly cleared from the plasma. The elimination half-life, which describes the time it takes for half the drug to be removed, is typically around two hours.


Q: What types of food should I eat or avoid while on Artemether?

A: Oral doses must be taken with food or a milky drink to ensure proper absorption and improve drug levels. Official warnings state that avoiding grapefruit or grapefruit juice is advised during treatment, as it can affect how the drug works.


Q: Can older adults or seniors take Artemether without special precautions?

A: Official regulatory information notes that specific pharmacokinetic studies have not been widely performed in patients older than 65 years of age. Therefore, the information available for this specific age group is generally limited.


Q: What are some signs of an allergic reaction to Artemether?

A: Reported signs of a severe allergic reaction can include anaphylaxis (a severe, life-threatening reaction) and angioedema. This may manifest as a skin rash, itching, hives, or swelling of the face, lips, tongue, or throat.


Q: Does Artemether affect your blood pressure?

A: Postmarketing safety reports have included rare cases of both high blood pressure (hypertension) and low blood pressure (hypotension). The potential for effects on blood pressure exists.


Q: Is Artemether effective against all types of human malaria?

A: No, official product information indicates that the medicine is specifically approved for treating acute, uncomplicated malaria caused by the Plasmodium falciparum parasite. It is not currently approved for use against or evaluated in the treatment of malaria caused by Plasmodium species other than P. falciparum.


Q: Do certain medications for chronic conditions interact negatively with Artemether?

A: Regulatory documents indicate that medications that strongly affect the CYP3A4 liver enzyme system or that are known to prolong the QT interval (an electrical change in the heart) are generally advised against. These interactions may involve some medicines for chronic conditions.


Q: Can Artemether cause changes in mood or sleep patterns?

A: Yes, changes in sleep patterns are listed as adverse reactions, including insomnia (difficulty sleeping). Official documents also report instances of mood swings and agitation.


Q: Are there any specific supplements or vitamins that should be avoided with Artemether?

A: Official drug interaction warnings specifically state that the herbal supplement St. John's wort is a strong CYP3A4 inducer that is formally prohibited. Other supplements that affect liver enzymes may also carry a risk.


Q: What happens if Artemether is taken past its expiration date?

A: The official protocol advises that unused or expired medicine must be disposed of according to local regulatory requirements. Disposal must avoid discharge into the environment or wastewater systems.


Q: How long after finishing the Artemether course is the malaria considered cured?

A: In clinical trials, doctors typically monitor the drug’s effectiveness, known as the Adequate Clinical and Parasitological Response (ACPR). This is checked at follow-up intervals, commonly on Day 28 or Day 42 after starting the course.


Q: What is the main benefit of Artemether compared to older malaria drugs?

A: According to official descriptions, the main benefit is its rapid speed of action. It is classified as a fast-acting blood schizonticide, which allows for a quick reduction of the parasite population in the blood compared to many conventional antimalarial treatments.


Q: What is the role of Artemether in 'Artemisinin-based Combination Therapy' (ACT)?

A: In ACT, Artemether's role is to provide the immediate, rapid, and high-level clearance of the parasite population. This fast action is then complemented by the long-acting partner drug, which sustains inhibitory pressure over time to prevent relapse.


Q: What are the typical instructions for taking Artemether with water?

A: The tablets are taken orally, typically with food. If an individual is unable to swallow, regulatory procedures allow the tablets to be crushed and mixed with a small amount of liquid or soft food, which should then be consumed immediately.


Q: Can Artemether be used in individuals with certain genetic disorders like G6PD deficiency?

A: While the official label does not list G6PD deficiency as a formal contraindication, the safety of the drug has been evaluated in this population in clinical trials. The use of the drug in individuals with this or other genetic disorders is subject to clinical consideration by a healthcare professional.


Q: What is the difference between Artemether and Lumefantrine?

A: Artemether is an artemisinin derivative that is rapid and fast-acting. Lumefantrine, the other component in the combination therapy, is a synthetic aryl amino alcohol that is slow-acting with a long half-life, providing sustained parasite clearance.


Q: Can children take Artemether safely?

A: Official restrictions state that the medicine is indicated for children with a bodyweight of 5 kg and above. Safety and effectiveness have not been established in infants who weigh less than 5 kg.


Q: What happens if I miss a dose of Artemether?

A: Official drug instructions state that if a dose is missed, it should be taken as soon as it is remembered. However, a double dose should not be taken to make up for a forgotten dose.


Q: Does Artemether interact with birth control pills?

A: Official warnings state that the effectiveness of hormonal contraceptives, including birth control pills, may be reduced by the artemether regimen. For patients using hormonal contraceptives, an alternative non-hormonal or barrier method may be necessary during therapy.


Q: Does Artemether affect your liver function?

A: Artemether is processed by the liver using the CYP3A4 enzyme. Official warnings state that caution and monitoring are required for patients with severe liver impairment, as clinical data in this specific group is limited.


Q: Is Artemether safe for people with kidney problems?

A: Official guidance advises that patients with severe kidney (renal) impairment should use the medicine with caution. This caution is due to limited clinical data available regarding the drug’s safety in this specific patient group.


Q: Is it better to take Artemether with food or on an empty stomach?

A: Oral doses must be taken with food or a milky drink. This requirement is mandated by the regulatory bodies because taking the medicine with food is necessary to ensure proper absorption and achieve adequate drug levels in the blood.


Q: Why does Artemether have to be taken for a specific number of days?

A: The treatment is mandated as a full course of six doses over three days to ensure comprehensive parasite clearance. This specific schedule ensures that the fast-acting Artemether rapidly clears the parasites, and the partner drug sustains inhibitory pressure over time to prevent relapse.

How should Artemether be stored and disposed of?

How to Store and Dispose of Artemether

Official regulatory guidelines mandate specific conditions for storing and disposing of Artemether to maintain its quality and ensure environmental safety.

Storage and Handling Requirements
Temperature: Store at room temperature, not exceeding 30°C.
Protection: Keep the medication in its original, tightly closed container and protect it from light and excess moisture.
Child Safety: The product must be stored out of the reach and sight of children.
Stability: If the injection is a multi-dose vial, it must be discarded after 28 days of initial opening.

Disposal Protocol

Unused or expired Artemether must be disposed of according to local regulatory requirements. Disposal must avoid discharge into the environment or wastewater systems. If a local drug take-back program is unavailable, follow authorized governmental guidance for household disposal, ensuring the product is sealed and mixed with undesirable waste before being placed in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Artemether found in:

A-Z Index: